Clinical Trial: A Phase 1/2 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Sponsor and Collaborators
Synta Pharmaceuticals Corp.

Contact
Contact: Robert Bradley
781-541-7985
rbradley@syntapharma.com

Principal Investigator
Jeffrey E Lancet, MD

ClinicalTrials.gov Identifier
NCT00964873